HANSA BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.32 SEK | +0.44% |
|
-6.76% | +4.27% |
| Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
| Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechJohan Unnerus (Analysts)My name is Johan Unnerus. I'm an analyst at the life s...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Companyâs operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeSâs goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Companyâs patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Calendar
2024-05-13
- Capital One Biotech Disruptors Conference
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
27.2
SEK
Average target price
105
SEK
Spread / Average Target
+286.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.27% | 137M | |
| +2.05% | 42.59B | |
| +8.26% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +9.24% | 24.81B | |
| -24.34% | 18.17B | |
| +27.45% | 12.05B | |
| -3.10% | 11.7B | |
| +6.96% | 11.1B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Transcript : Hansa Biopharma AB - Special Call
